SolasCure

SolasCure is a clinical-stage biotech addressing the significant unmet need in chronic wound healing with its lead candidate, Aurase Wound Gel. The biologic has completed a second Phase II trial, demonstrating accelerated healing compared to standard care. The company has secured substantial non-dilutive grant funding from UK and EU bodies and is led by a team with deep wound care and biotech experience. SolasCure is positioned to advance a first-in-class therapeutic that combines continuous debridement with active stimulation of healing biology.

Biologic gel platform combining continuous enzymatic debridement with activation of endogenous tissue repair pathways.

SolasCure competes in the advanced wound care market against large medtech firms (e.g., Smith & Nephew, Mölnlycke) offering advanced dressings and devices, and other biotech companies developing growth factors and cell therapies. Its differentiation lies in the dual-action biologic approach designed to actively restart healing biology, rather than provide passive management.